The Changing Field of Melanoma: Ipilimumab

The Changing Field of Melanoma: BRAF Mutations

The Changing Field of Melanoma: PD-1 and PD-L1 Antibodies

Preferred Regimens for Metastatic Melanoma

Considerations With the New Agents

First-Line Therapy for Patients With BRAF Mutation

First-Line Therapy for Patients With BRAF Wild Type

Immune-Related Response Criteria

Investigational PD-1 Inhibitors

Investigational Combination Therapy

Questions to Be Answered About PD-1-Blocking Antibodies

Other Investigational Approaches

Other Investigational Approaches (cont)

Investigational Combination Approaches

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)